Keywords: ناتالیزوماب; Natalizumab; Vaginitis; Probiotics; Adverse effects; Multiple sclerosis;
مقالات ISI ناتالیزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ناتالیزوماب; Natalizumab; Extended; Dosing interval; Efficacy; Multiple sclerosis;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Rebound; Epstein-Barr virus; Virus-specific CD8+ T lymphocytes; Immune reconstitution inflammatory syndrome;
Keywords: ناتالیزوماب; Central nervous system; Craniotomy; Crohn disease; Lymphoma; Multiple sclerosis; Natalizumab; Tsyabri; EBV; Epstein-Barr virus; FDA; Food and Drug Administration; HHV; Human herpesvirus; HIV; Human immunodeficiency virus; Ig; Immunoglobulin; LPD; Lymphopr
Keywords: ناتالیزوماب; Melanoma; Multiple sclerosis; Natalizumab;
Keywords: ناتالیزوماب; Myocardial infarction; Multiple sclerosis; Natalizumab;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Fingolimod; Disease modifying drugs; Drug Switching; Immunomodulation; PE; primary endpoint; SE; secondary endpoint; REA; recurrent event analysis; PML; progressive multifocal leukoencephalopathy; aPBVC; annualized percent
Keywords: ناتالیزوماب; Multiple sclerosis; Alemtuzumab; Dimethyl fumarate; Fingolimod; Natalizumab; Teriflunomide; Adverse effects; Depression; Anxiety; Systematic review;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Post-mortem; Histopathology; Epstein-Barr virus; Cytotoxic T lymphocytes;
Keywords: ناتالیزوماب; Natalizumab; Progressive multifocal leukoencephalopathy; Immune reconstitution inflammatory syndrome; Maraviroc;
Keywords: ناتالیزوماب; multiple sclerosis; pediatric; natalizumab; EDSS; Kuwait;
Keywords: ناتالیزوماب; BDNF; MS; Natalizumab;
Keywords: ناتالیزوماب; Multiple sclerosis; Relapsing-remitting; Natalizumab; Monoclonal antibodies; Treatment outcome;
Keywords: ناتالیزوماب; DMT; disease modifying therapy; EDSS; Expanded Disability Status Scale; MRI; magnetic resonance imaging; MS; multiple sclerosis; Relapsing-remitting multiple sclerosis; Disease modifying therapy; Natalizumab; Fingolimod; Alemtuzumab; Systematic review;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; Risk perception; Risk attribution; Risk knowledge; Shared decision making;
Keywords: ناتالیزوماب; Health-related quality of life; Multiple sclerosis; Natalizumab; Fatigue; Depression; Cognition;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Erythroblasts;
Keywords: ناتالیزوماب; immune-reconstitution inflammatory syndrome; JC virus; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Effectiveness; Safety; Observational study; Real-world
Keywords: ناتالیزوماب; Multiple sclerosis; No Evidence of Disease Activity; Disease-modifying treatments; Natalizumab;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Monocytes
Keywords: ناتالیزوماب; Natalizumab; Hepatotoxicity; Autoimmune hepatitis; Drug-induced liver injury;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Biomarkers; Neurofilament; Cerebrosterol; 24S-hydroxycholesterol; 27-hydroxycholesterol; SDMT; Cerebrospinal fluid; Neurodegeneration; Blood-brain barrier;
Keywords: ناتالیزوماب; Bénéfice-risque; LEMP; Natalizumab; Sclérose en plaques; Sérologie JCV; Benefit-risk; PML; Natalizumab; Multiple sclerosis; JCV serology;
Keywords: ناتالیزوماب; PML; JCV; Natalizumab; Multiple sclerosis
Keywords: ناتالیزوماب; Melatonin; Natalizumab; Oxidative stress; Relapsing-remitting multiple sclerosis; Tysabri®;
Keywords: ناتالیزوماب; Fingolimod; Glatiramer acetate; Interferon; Multiple sclerosis; Natalizumab; Prescribing; Utilisation
Keywords: ناتالیزوماب; Varicella zoster virus; Multiple sclerosis; Virus and multiple sclerosis; Fingolimod; Natalizumab;
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Immunization; Vaccines; Immunoglobulins; Lymphocytes; Immunity; Humoral;
Keywords: ناتالیزوماب; Multiple sclerosis; Vaccine; Efficacy; Natalizumab;
Keywords: ناتالیزوماب; Natalizumab; Progressive multifocal leukoencephalopathy; Immune reconstitution inflammatory syndrome; Multiple sclerosis; Treatment; Adverse events;
Keywords: ناتالیزوماب; Multiple sclerosis; Tremor; Neurologic symptoms; Natalizumab; Self-report; Questionnaires;
Keywords: ناتالیزوماب; immune therapy; multiple sclerosis; interferon; glatiramer; natalizumab; fumarate;
Keywords: ناتالیزوماب; ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Keywords: ناتالیزوماب; ADA; anti-drug antibody; ABT; antigen binding test; GSH; reduced glutathione; Natalizumab; Certolizumab; Anti-drug antibody (ADA); Bispecific antibody; Drug interference;
Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Daclizumab; Alemtuzumab;
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Keywords: ناتالیزوماب; Disability worsening; Natalizumab; Relapsing-remitting multiple sclerosis; EDSS milestones; CP; cumulative probability; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; RRMS; relapsing-remitting multiple sclerosis; SPMS; secondary p
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: ناتالیزوماب; Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
Keywords: ناتالیزوماب; AE; adverse event; ARR; annualized relapse rate; DMF; dimethyl fumarate; DMT; disease-modifying therapy; HR; hazard ratio; IPTW; inverse probability of treatment weight; JCV; John Cunningham virus; MS; multiple sclerosis; PML; progressive multifocal leuko
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients
Keywords: ناتالیزوماب; Natalizumab; Multiple sclerosis; Lymphocytes; CD4; CD8;
Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population
Keywords: ناتالیزوماب; Multiple Sclerosis; JC virus; Natalizumab; Risk stratification; Progressive Multifocal Leukoencephalopathy;
Review articleClassifying PML risk with disease modifying therapies
Keywords: ناتالیزوماب; Disease modifying therapy; Multiple sclerosis; Progressive multifocal leukoencephalopathy; Natalizumab; Fingolimod; Dimethyl fumarate; Rituximab;
Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis
Keywords: ناتالیزوماب; JC virus; Cytokines; Natalizumab;
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch
Keywords: ناتالیزوماب; Biomarkers; Natalizumab; Fingolimod; Multiple sclerosis; Treatment change; Flow cytometry;
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma
Keywords: ناتالیزوماب; MS; multiple sclerosis; NTZ; natalizumab; VLA-4; very late antigen-4; VCAM-1; vascular cell adhesion protein-1; aNK cells; polyclonal activated NK cells; fNK cells; freshly isolated NK cells; NK cells; Melanoma; Natalizumab; Multiple sclerosis; VLA-4;
Characterization of naïve, memory and effector T cells in progressive multiple sclerosis
Keywords: ناتالیزوماب; T cells; Progressive MS; Memory; CD26; CD49; Natalizumab;
Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation
Keywords: ناتالیزوماب; Multiple sclerosis; Natalizumab; Microglia/Macrophages; PK11195-PET; Lesion;
Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis
Keywords: ناتالیزوماب; Multiple Sclerosis; Disease modifying therapies; Immunology; Relapsing/remitting; Natalizumab; SVCAM-1;
Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report
Keywords: ناتالیزوماب; Natalizumab; JC virus; Progressive multifocal leukoencephalopathy; Influenza vaccination;
Extratemporal herpes encephalitis during natalizumab treatment: A case report
Keywords: ناتالیزوماب; HSV-1; Encephalitic; Multiple sclerosis; Natalizumab;